Updated May 2026 · SEC EDGAR data
Amgen Inc., Q1 2024 Earnings
Healthcare · Period ending 2024-03-31
Amgen Inc. (AMGN) reported Q1 2024 earnings to the SEC: revenue of N/A, EPS of $-0.21, and net income of $-113.0M. Sourced directly from Amgen Inc.'s SEC EDGAR XBRL filings. Sector: Healthcare.
Headline Numbers
Q1 2024 in Context
Amgen Inc. reported Q1 2024 results to the SEC. Comparison data for prior quarters is not available for this period in the EarningsCallAI database.
The NEUTRAL Operator Read
Across the 8 quarters tracked, Amgen Inc. carries an operator signal of NEUTRAL with low confidence. Recent quarters are roughly flat; management commentary is steady-state. No major directional signal for operators in adjacent markets.
How This Data Was Sourced
All numbers on this page come directly from Amgen Inc.'s SEC EDGAR filing for Q1 2024. EDGAR is the U.S. Securities and Exchange Commission's public filing system; quarterly results are filed on Form 10-Q and annual results on Form 10-K. XBRL tagging ensures revenue means revenue across every filer. The earnings press release is typically furnished as a Form 8-K. Both forms are public domain. Read the methodology for the operator-signal classification rules.
Frequently Asked Questions
What did Amgen Inc. report in Q1 2024?
Amgen Inc. reported revenue of N/A, EPS of $-0.21, and net income of $-113.0M for Q1 2024. Figures come from the company's SEC EDGAR XBRL filing.
Where does this earnings data come from?
All numbers on this page are pulled directly from Amgen Inc.'s SEC EDGAR XBRL filing for Q1 2024 (Form 10-Q for quarterly results, Form 10-K for annual). EDGAR is the SEC's public filing system; XBRL is a structured tagging standard that ensures revenue means revenue across every filer. Data is in the public domain.
What is Amgen Inc.'s current operator signal?
Amgen Inc. currently carries a NEUTRAL operator signal with LOW confidence. The signal is calculated across all available quarters, not just this one, and combines a quantitative read of revenue trajectory with a qualitative read of management commentary. Read the methodology page for the formal classification rules.
Is this earnings analysis investment advice?
No. EarningsCallAI is built for business operators evaluating market trends, demand signals, and competitive dynamics, not for stock trading decisions. Operator signals are not buy/sell recommendations. Always consult a licensed financial advisor before making investment decisions.
When was the Q1 2024 report filed?
Amgen Inc. filed its Q1 2024 results to the SEC for the period ending 2024-03-31. Quarterly filings (10-Q) are typically due within 40 days of period end for large accelerated filers; annual reports (10-K) are typically due within 60 days.
Amgen Inc. (AMGN) reported Q1 2024 earnings to the SEC: revenue of N/A, EPS of $-0.21, and net income of $-113.0M. Sourced directly from Amgen Inc.'s SEC EDGAR XBRL filings. Sector: Healthcare.
The this entity record above pulls directly from SEC EDGAR 8-K filings. What follows is the per-entity context — how this entity sits in the broader U.S. public-company earnings disclosures distribution and which underlying factors drive the headline numbers.
Every number on this page links back to SEC EDGAR 8-K filings; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. public companies. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.